

Arbuckle Stuart A
Form 4
July 21, 2017

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Arbuckle Stuart A

2. Issuer Name **and** Ticker or Trading
Symbol
VERTEX PHARMACEUTICALS
INC / MA [VRTX]

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

(Last) (First) (Middle)
C/O VERTEX
PHARMACEUTICALS
INCORPORATED, 50 NORTHERN
AVENUE

3. Date of Earliest Transaction
(Month/Day/Year)
07/19/2017

____ Director ____ 10% Owner
X Officer (give title below) ____ Other (specify below)
EVP/Chief Commercial Officer

(Street)
BOSTON, MA 02210

4. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check
Applicable Line)
X Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount (A) or (D)	Price	
Common Stock	07/19/2017		M		25,500 A	\$ 96.87	156,967 D
Common Stock	07/19/2017		M		38,250 A	\$ 109.14	195,217 D
Common Stock	07/19/2017		M		14,875 A	\$ 131.89	210,092 D
Common Stock	07/19/2017		M		10,775 A	\$ 91.05	220,867 D

Edgar Filing: Arbuckle Stuart A - Form 4

Common Stock	07/19/2017	S ⁽¹⁾	60,400	D	\$ 161	160,467	D	
Common Stock	07/19/2017	S ⁽¹⁾	29,000	D	\$ 162.67	131,467	D	
Common Stock	07/21/2017	M	2,125	A	\$ 131.89	133,592	D	
Common Stock	07/21/2017	S ⁽¹⁾	2,125	D	\$ 159	131,467	D	
Common Stock	07/21/2017	S ⁽¹⁾	10,150	D	\$ 161.68	121,317	D	
Common Stock	07/21/2017	S ⁽¹⁾	200	D	\$ 161.72	121,117	D	
Common Stock						140	I	401(k)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Amount or Number of Shares	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 96.87	07/19/2017		M		25,500		<u>(2)</u>	07/14/2024	Common Stock	25,500
Stock Option (Right to Buy)	\$ 109.14	07/19/2017		M		38,250		<u>(3)</u>	02/02/2025	Common Stock	38,250
Stock Option (Right to Buy)	\$ 131.89	07/19/2017		M		14,875		<u>(4)</u>	07/20/2025	Common Stock	14,875

Buy)

Stock

Option
(Right to
Buy)

\$ 91.05

07/19/2017

M

10,775

(5)

02/01/2026

Common
Stock

10,775

Stock

Option
(Right to
Buy)

\$ 131.89

07/21/2017

M

2,125

(4)

07/20/2025

Common
Stock

2,125

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Arbuckle Stuart A
C/O VERTEX PHARMACEUTICALS
INCORPORATED
50 NORTHERN AVENUE
BOSTON, MA 02210

EVP\Chief Commercial
Officer

Signatures

Omar White,
Attorney-In-Fact

07/21/2017

 Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1.

(2) The option vests in 16 quarterly installments from 07/15/2014.

(3) The option vests in 16 quarterly installments from 02/03/2015.

(4) The option vests in 16 quarterly installments from 07/21/2015.

(5) The option vests in 16 quarterly installments from 02/02/2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.